Outcome analysis and associations with Charlson comorbidity index in the early-stage lung cancer patients treated with stereotactic radiotherapy

Read full text Summarise with VIRAT
Authors: Dasantha T. Jayamanne, Tanvi Suri, Sarah Bergamin, Gabrielle Metz, Benjamin Harris, Garrick W. Don, Michael Hibbert, Michael Harden, Levi Bassin, Venkatesha Venkatesha, Aoife Conway, Stephen Clarke
Cited by: 0
References: 26

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Lung stereotactic body radiotherapy (SBRT) is the standard of care for patients with inoperable early-stage non-small cell lung cancer (NSCLC), who frequently have significant comorbidities. There is no standardised method to predict how age and comorbidities influence SBRT efficacy or toxicity. The Charlson Comorbidity Index (CCI) and its age-adjusted variant (aCCI) have been proposed as prognostic tools, though their predictive value remains uncertain. This study assessed the prognostic relevance of the CCI and aCCI in patients undergoing SBRT for early-stage NSCLC. METHODS: This retrospective single-institution study included patients with NSCLC treated with SBRT between January 2010 and December 2023. Patients receiving standard SBRT dose-fractionation for peripheral, central, and ultracentral tumours were eligible. CCI and aCCI scores were calculated for all patients. The primary objective was to compare overall survival (OS) between patients with low (< 2) and high (≥ 2) CCI scores. Secondary outcomes included associations of CCI and aCCI with OS, cancer-specific survival (CSS), local failure (LF), regional failure (RF), distant failure (DF), and treatment-related toxicity. Cox proportional hazards regression was used. RESULTS: A total of 170 patients were included, with a median age of 77 years (range: 51–93). After a median follow-up of 36.4 months, 68 deaths occurred, including 24 cancer-specific deaths. Median OS was 59.4 months (95% CI: 49.9–104.1), while median CSS was not reached. High CCI (> 2) was not associated with worse OS (univariate: HR 0.97, 95% CI: 0.43–2.16, p = 0.93; multivariate: HR 0.16, 95% CI: 0.03–0.92, p = 0.04). High aCCI (> 6) was also not significantly associated with OS (HR 1.02, 95% CI: 0.43–2.38, p = 0.97). Patients with peripheral tumours had a significantly higher risk of death than those with central tumours (HR 4.7 × 10⁹, 95% CI: 1.1 × 10⁹–2.01 × 10¹⁰, p < 0.001). No other variables significantly influenced survival. SBRT was well tolerated, with no grade 4–5 toxicities or treatment-related deaths. CONCLUSIONS: The CCI and aCCI did not predict overall or disease-specific survival in patients treated with SBRT for early-stage NSCLC. These findings suggest that current comorbidity indices may be inadequate in this population and highlight the need for improved prognostic tools to guide treatment decisions.

Fields of Study & Subjects

Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies Frailty in Older Adults

Publication details

Journal / source
BMC Cancer
Volume
26
Issue
1
Publication date
20 March 2026
Language
EN